Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of oral TNO155 alone or with nazartinib in advanced solid tumors
NL-OMON54714Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of batoprotafib and nazartinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 3 more (8 arms), sponsored by Novartis. Primary endpoints: Adverse effects, Dose-limiting toxicities and 1 more. Started Jun 2017; status: recruiting.
02
Drugs
batoprotafibnazartinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)gastrointestinal stromal tumor (GIST)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NL-OMON54714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54714.